Why the study?
Little is known about the role of interleukins in acute myocardial infarction, especially soluble IL-2 receptor and IL-8, in predicting future major adverse cardiovascular events compared with established biomarkers.
Do high serum levels of sIL-2R and IL-8 predict future major adverse cardiovascular events in patients with acute myocardial infarction?
Population
173 patients with acute MI
Comparison
High vs low levels of sIL-2R, IL-8, and other interleukins
Design
Prospective, single-center cohort study
Follow-up
1-year and a median of 2.2 years
Key result
High serum sIL-2R and IL-8 levels were significantly associated with an increased risk of major adverse cardiovascular events (sIL-2R HR 7.7; IL-8 HR 4.8) at 1-year follow-up in patients with acute myocardial infarction.
Authors
Loading...
May support post-AMI risk stratification; hypothesis-generating and requires validation before clinical adoption.
Cohort (n=173)
No
Do high serum levels of sIL-2R and IL-8 predict future major adverse cardiovascular events in patients with acute myocardial infarction?
Hazard Ratio: 7.7 (95% CI 3.3–18)
p-value: p=<0.001
High serum levels of sIL-2R and IL-8 are independent predictors of major adverse cardiovascular events in patients with acute myocardial infarction, offering superior predictive value compared to current biomarkers.
Pan et al. (2023) conducted a cohort in Acute myocardial infarction (n=173). High serum sIL-2R levels vs. Low serum sIL-2R levels was evaluated on Major adverse cardiovascular events (MACEs) at 1-year follow-up (HR 7.7, 95% CI 3.3-18.0, p=<0.001). High serum sIL-2R and IL-8 levels were significantly associated with an increased risk of major adverse cardiovascular events (sIL-2R HR 7.7; IL-8 HR 4.8) at 1-year follow-up in patients with acute myocardial infarction.